4//SEC Filing
JENSEN JESSICA D. 4
Accession 0001104659-21-087831
CIK 0001811764other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 9:30 PM ET
Size
6.2 KB
Accession
0001104659-21-087831
Insider Transaction Report
Form 4
JENSEN JESSICA D.
EVP Clinical Development
Transactions
- Award
Stock Option (Right to Buy)
2021-06-30+125,553→ 125,553 totalExercise: $6.97Exp: 2026-07-20→ Common Stock (125,553 underlying)
Footnotes (2)
- [F1]On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each option to acquire shares of Old POINT was exchanged for an option to acquire shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported options to acquire the Issuer's Common Stock in consideration for the options to acquire equity securities of Old POINT held by the Reporting Person prior to the Business Combination.
- [F2]The option is fully vested.
Documents
Issuer
POINT Biopharma Global Inc.
CIK 0001811764
Entity typeother
Related Parties
1- filerCIK 0001868742
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 9:30 PM ET
- Size
- 6.2 KB